Skip to main content
Scott Tagawa, MD, Oncology, New York, NY, New York-Presbyterian Hospital

ScottTTagawaMDMS

Oncology New York, NY

Genitourinary Oncology, Hematologic Oncology

Professor of Medicine & Urology; Medical Director, Genitourinary Oncology Research Program

Overview of Dr. Tagawa

Dr. Scott Tagawa, MD is an oncologist in New York, New York. He is currently licensed to practice medicine in New York and California. He is affiliated with New York-Presbyterian Hospital.

Education & Training

  • Weill Cornell Graduate School of Medical SciencesMS, Clinical Investigation, 2007 - 2010
  • University of Southern California/LACUSC Medical Center
    University of Southern California/LACUSC Medical CenterFellowship, Medical Oncology, 2002 - 2005
  • University of Southern California/LACUSC Medical Center
    University of Southern California/LACUSC Medical CenterResidency, Internal Medicine, 1998 - 2001
  • University of Southern California School of Medicine
    University of Southern California School of MedicineClass of 1998
  • Georgetown University
    Georgetown UniversityBS, Biology, 1989 - 1993

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2005 - 2022
  • CA State Medical License
    CA State Medical License 2000 - Present
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2012-2014
  • Top Doctors: New York Metro Area Castle Connolly, 2010-2014
  • America's Top Doctors for Cancer Castle Connolly, 2009, 2011-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemothera... 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

  • Sacituzumab Govitecan Shows Promise in Urothelial Cancer
    Sacituzumab Govitecan Shows Promise in Urothelial CancerMarch 23rd, 2017
  • Sacituzumab Govitecan Demonstrates Early Efficacy in Heavily Pretreated Metastatic Urothelial Cancer
    Sacituzumab Govitecan Demonstrates Early Efficacy in Heavily Pretreated Metastatic Urothelial CancerSeptember 28th, 2019
  • ESMO 2019: Initial Results from TROPHY-U-01: A Phase 2 Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Cancer After Failure of Platinum-Based Regimens or Immunotherapy
    ESMO 2019: Initial Results from TROPHY-U-01: A Phase 2 Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Cancer After Failure of Platinum-Based Regimens or ImmunotherapySeptember 29th, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    Altius Provider Directory
    BCBS Blue Card PPO
    BCBS Illinois BlueChoice Select
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    First Health PPO
    GHI PPO
    Great West PPO
    Healthfirst New York
    HIP of New York - Select PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment